We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Development of a Novel CD26-Targeted Chimeric Antigen Receptor T-Cell Therapy for CD26-Expressing T-Cell Malignancies.
- Authors
Kobayashi, Eiji; Kamihara, Yusuke; Arai, Miho; Wada, Akinori; Kikuchi, Shohei; Hatano, Ryo; Iwao, Noriaki; Susukida, Takeshi; Ozawa, Tatsuhiko; Adachi, Yuichi; Kishi, Hiroyuki; Dang, Nam H.; Yamada, Taketo; Hayakawa, Yoshihiro; Morimoto, Chikao; Sato, Tsutomu
- Abstract
Chimeric-antigen-receptor (CAR) T-cell therapy for CD19-expressing B-cell malignancies is already widely adopted in clinical practice. On the other hand, the development of CAR-T-cell therapy for T-cell malignancies is in its nascent stage. One of the potential targets is CD26, to which we have developed and evaluated the efficacy and safety of the humanized monoclonal antibody YS110. We generated second (CD28) and third (CD28/4-1BB) generation CD26-targeted CAR-T-cells (CD26-2G/3G) using YS110 as the single-chain variable fragment. When co-cultured with CD26-overexpressing target cells, CD26-2G/3G strongly expressed the activation marker CD69 and secreted IFNgamma. In vitro studies targeting the T-cell leukemia cell line HSB2 showed that CD26-2G/3G exhibited significant anti-leukemia effects with the secretion of granzymeB, TNFα, and IL-8, with 3G being superior to 2G. CD26-2G/3G was also highly effective against T-cell lymphoma cells derived from patients. In an in vivo mouse model in which a T-cell lymphoma cell line, KARPAS299, was transplanted subcutaneously, CD26-3G inhibited tumor growth, whereas 2G had no effect. Furthermore, in a systemic dissemination model in which HSB2 was administered intravenously, CD26-3G inhibited tumor growth more potently than 2G, resulting in greater survival benefit. The third-generation CD26-targeted CAR-T-cell therapy may be a promising treatment modality for T-cell malignancies.
- Subjects
CHIMERIC antigen receptors; MONOCLONAL antibodies; T cells; ANTIGEN receptors; T-cell lymphoma; CD26 antigen
- Publication
Cells (2073-4409), 2023, Vol 12, Issue 16, p2059
- ISSN
2073-4409
- Publication type
Article
- DOI
10.3390/cells12162059